Profound Medical (PROF) Price & Analysis

80 Followers

PROF Stock Chart & Stats

$7.37

-$0.03(-0.33%)

At close: Jan 08 4:00 PM EST

$7.37

-$0.03(-0.33%)

Day’s Range― - ―

52-Week Range$3.76 - $8.95

Previous CloseN/A

Volume13.91K

Average Volume (3M)136.84K

Market Cap

$241.08M

Enterprise Value$157.64M

Total Cash (Recent Filing)$50.33M

Total Debt (Recent Filing)$7.47M

Price to Earnings (P/E)―

Beta0.82

Next Earnings

Jul 30, 2026

EPS Estimate

-0.24

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.24

Shares Outstanding36,337,640

10 Day Avg. Volume105,290

30 Day Avg. Volume136,840

Financial Highlights & Ratios

PEG Ratio-0.20

Price to Book (P/B)3.58

Price to Sales (P/S)14.48

P/FCF Ratio-6.07

Enterprise Value/Market Cap0.65

Enterprise Value/Revenue8.40

Enterprise Value/Gross Profit11.83

Enterprise Value/Ebitda-4.32

Forecast

1Y Price Target

$11.00

Price Target Upside49.25% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-0.6

Revenue Forecast (FY)$19.63M

Bulls Say, Bears Say

Bulls Say

Growth GuidanceProfound reported Q4 results mostly in line with expectations and guided to 70%-75% growth this year, with the opportunity to reach triple-digit growth rates next year and beyond.

Reimbursement RatesTULSA received a substantially higher reimbursement rate for 2025 from CMS than RARP, potentially making it more profitable for many institutions.

Tariff And Trade ComplianceProfound is almost certainly unlikely to face any challenges on tariff concerns as the company is USMCA compliant, allowing their products to be traded duty-free.

Bears Say

Market CompetitionProfound is bringing more attention to the BPH opportunity and addressed Procept BioRobotics’ Aquablation, highlighting TULSA's unique versatility.

Profound Medical News

Profound Medical Shareholders Back Board, Question Incentive Plan

An announcement from Profound Medical ( ($TSE:PRN) ) is now available. At its Annual General and Special Meeting...

2M ago

PROF

Telix announces LoI to collaborate with EDAP TMS and Profound Medical

Telix Pharmaceuticals (TLX) announces that it has entered into letters of intent, or LoI, to pursue collaborations with...

2M ago

EDAP

PROF

Profound Medical Highlights TULSA Advances at AUA 2026

Profound Medical ( ($TSE:PRN) ) has provided an update. On May 14, 2026, Profound Medical announced that its...

2M ago

PROF

Profound Medical files to sell 921,428 common shares for holders

17:07 EDT Profound Medical (PROF) files to sell 921,428 common shares for holders Published first on TheFly –...

2M ago

PROF

Profound Medical price target lowered to $10 from $12 at Stifel

Stifel analyst Rick Wise lowered the firm’s price target on Profound Medical (PROF) to $10 from $12 and...

2M ago

PROF

Profound Medical Schedules First-Quarter 2026 Earnings Release

Profound Medical ( ($TSE:PRN) ) has issued an update. Profound Medical Corp., a commercial-stage medical device maker, develops...

3M ago

PROF

Profound Medical to Present Business Update at Conference

Profound Medical ( ($TSE:PRN) ) just unveiled an update. On April 14, 2026, Profound Medical Corp. announced that...

3M ago

PROF

Profound Medical Showcases TULSA-PRO at Key Radiology Meeting

The latest update is out from Profound Medical ( ($TSE:PRN) ). Profound Medical’s TULSA-PRO platform and its incision-free,...

3M ago

PROF

Profound Medical Marks Key TULSA Milestone as Texas Prostate Tops 100 Procedures

The latest update is out from Profound Medical ( ($TSE:PRN) ). Profound Medical Corp., a commercial-stage medical device...

3M ago

PROF

Profound Medical Trial Shows TULSA Improves Prostate Cancer Outcomes

Profound Medical ( ($TSE:PRN) ) has issued an update. On March 13, 2026, Profound Medical announced that its...

4M ago

PROF

Profound Medical reports CAPTAIN trial meets primary safety endpoint

Profound Medical (PROF) announced superiority on the prespecified, primary safety endpoint in the Level 1 post-market CAPTAIN randomized...

4M ago

PROF

Profound Medical Announces Board Resignation and New Appointment

The latest announcement is out from Profound Medical ( ($TSE:PRN) ). On March 5, 2026, Profound Medical Corp....

4M ago

PROF

Profound Medical to Present First CAPTAIN Trial Results and Steps Up Investor Outreach

Profound Medical ( ($TSE:PRN) ) just unveiled an update. Profound Medical will unveil the first clinical outcomes from...

4M ago

PROF

Profound Medical pullback after Q4 report ‘misguided,’ says Lake Street

Lake Street analyst Ben Haynor views last Friday’s reaction to Profound Medical’s (PROF) Q4 results as “misguided” and...

4M ago

PROF

PROF FAQ

What was Profound Medical’s price range in the past 12 months?

Profound Medical lowest stock price was $3.76 and its highest was $8.95 in the past 12 months.

What is Profound Medical’s market cap?

Profound Medical’s market cap is $241.08M.

When is Profound Medical’s upcoming earnings report date?

Profound Medical’s upcoming earnings report date is Jul 30, 2026 which is in 28 days.

How were Profound Medical’s earnings last quarter?

Profound Medical released its earnings results on May 07, 2026. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.25 by $0.06.

Is Profound Medical overvalued?

According to Wall Street analysts Profound Medical’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Profound Medical pay dividends?

Profound Medical does not currently pay dividends.

What is Profound Medical’s EPS estimate?

Profound Medical’s EPS estimate is -0.24.

How many shares outstanding does Profound Medical have?

Profound Medical has 36,337,640 shares outstanding.

What happened to Profound Medical’s price movement after its last earnings report?

Profound Medical reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.25. Following the earnings report the stock price went down -4.33%.

Which hedge fund is a major shareholder of Profound Medical?

Currently, no hedge funds are holding shares in PROF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Profound Medical Stock Smart Score

Neutral

Analyst Consensus

Moderate Buy

Average Price Target:
$11.00 (49.25% Upside)

Technicals

Fundamentals

Return on Equity

-78.75%

Trailing 12-Months

Asset Growth

17.02%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Profound Medical

Profound Medical Corp., along with its subsidiaries, operates as a commercial-stage medical technology firm. The company specializes in creating magnetic resonance (MR) guided ablation therapies designed to address prostate conditions, uterine fibroids, and to provide palliative pain management. Its market reach extends to Canada, Germany, the United States, and Finland. The company's primary offering is the TULSA-PRO system, which is engineered to integrate with magnetic resonance imaging (MRI) scanners within hospitals and clinical treatment facilities. Additionally, Profound Medical offers Sonalleve, a versatile therapeutic platform that treats uterine fibroids, delivers palliative pain relief for bone metastases, and provides non-invasive solutions for uterine fibroid treatment. Profound Medical Corp. maintains its corporate headquarters in Mississauga, Canada.

Profound Medical (PROF) Earnings & Revenues

Historic Earnings Reports

PROF Stock 12 Month Forecast

Average Price Target

$11.00

▲(49.25% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","8":"$8","13":"$13","5.5":"$5.5","10.5":"$10.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,5.5,8,10.5,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.67,7.08,7.49,7.9,8.31,8.72,9.129999999999999,9.54,9.95,10.36,10.77,11.18,11.59,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.67,7.003076923076923,7.336153846153846,7.6692307692307695,8.002307692307692,8.335384615384616,8.668461538461539,9.001538461538463,9.334615384615384,9.667692307692308,10.000769230769231,10.333846153846153,10.666923076923077,{"y":11,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.67,6.926153846153846,7.182307692307692,7.438461538461539,7.694615384615385,7.950769230769231,8.206923076923077,8.463076923076922,8.71923076923077,8.975384615384616,9.231538461538461,9.487692307692308,9.743846153846153,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.49,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.102,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.94,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.07,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.42,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.87,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.76,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.46,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.53,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.86,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.67,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >